What Were Learning From Omada Members At Omada Health, we support hundreds of thousands of people each year in managing their weight health, affording us first-hand experience in whats happening in the real world
doi: 10.5114/pg.2020.95554 Damianos JA, Fredrick TW, Jin MF, Ospina-Velasquez L, Wang XJ
Navigating GLP-1 tapering after successful weight loss For many patients, GLP-1 therapy has been a game-changer for weight loss and metabolic health, but discontinuation often tells a different story
Data from RCTs largely support the ability of GLP-1 medicines to reduce rates of MACE in people with T2D, 88 and a single trial demonstrates reduced rates of MACE in semaglutide-treated patients with overweight or obesity
Accordingly, people with type 2 diabetes, cardiovascular disease, heart failure, or chronic kidney disease should be treated appropriately with an SGLT-2 inhibitor or GLP-1RA, even because more adults with type 2 diabetes in the US have suboptimal glycemic control now compared to 10 years ago, associated with a resurgence in vascular diabetic complications [32]